INTRODUCTION
Although in the ongoing battle against infectious diseases it is sometimes difficult to determine which side is winning, a number of new weapons have recently become available which promise to tilt the scales in our favor. These include the development of new candidate antiviral drugs, the sitespecific targeting of designer immunotoxins, the synthesis of milligram quantities of epitope-specific synthetic peptide antigens, and, most notably, the ability to construct genetically engineered recombinant viral vaccines. Since there are a considerable number of historical precedents for using viruses as effective vaccines (44), this last approach in particular holds considerable promise because a large number of different types of viruses can be adapted to serve as efficient and effective vectors (107) . Although each virus has its own set of unique advantages, which may prove useful in laboratory studies, the system that seems to hold the greatest immediate potential for human medicine is the use of infectious genetically engineered poxvirus recombinants. Several reviews have addressed the general methodology and the specific applications of the system for particular subdisciplines (14, 67, 73, 94, 102, 109, 110, 126, 142, 146, 147, 166) . However, because of the high level of research activity in this area, it is rapidly and constantly changing. The purpose of this review is to provide an updated overview of the use of poxvirus expression vectors with an emphasis on new methods that have recently become available, to consider both the advantages and disadvantages of this system, and finally, to preview what the future is likely to hold for poxvirus vectors.
VV BIOLOGY W Replication Cycle
Although a number of different poxviruses (e.g., fowlpox, cowpox, and raccoonpox) are now being used as vectors, the following remarks pertain primarily to vaccinia virus (VV), the prototype member of the poxvirus family which has been the focus of most of the efforts to develop poxvirus-based vector systems. VV is a large DNA-containing animal virus that replicates within the cytoplasm of susceptible host cells (69, 71) . The VV virion consists of a biconcave core particle, containing the viral genomic DNA molecule, which is flanked by two lateral bodies. The entire structure is enclosed within a lipid envelope. The basic major features of the VV replicative cycle are diagrammed in Fig. 1 .
The virus adsorbs to susceptible host cells and makes its way into the interior of the cell by either direct penetration or viropexis. Once viral immediate-early genes commences. This phase of transcription is carried out under the influence of viral enzymes which have been packaged into the virion (77) . These include VV DNA-dependent RNA polymerase, poly(A) polymerase, capping and methylating activities, and trans-acting transcription factors (108) . The immediate-early genes correspond to about one-half of the viral genetic potential, i.e., about 100 gene products (10, 118) . Included among the VV immediate-early gene products are enzymes required for viral DNA replication such as DNA polymerase (76) , thymidine kinase (68) , and ribonucleotide reductase (141, 163) , as well as virus-encoded enzymes necessary to catalyze the breakdown of the core particle (uncoating II) and release of the viral DNA molecule. Subsequent to core breakdown, but prior to DNA replication, a minor class of VV genes are transcribed (known as delayed-early genes) whose expression is essential for the replication of VV DNA (108) . About 3 h postinfection, viral DNA begins to be replicated by viral enzymes in the cytoplasm of infected cells. A pronounced shift in the pattern of VV transcription and translation occurs concomitantly with the onset of viral DNA replication. That is, the transcription of VV early genes and the translation of the resulting early transcripts are attenuated, whereas the transcription and expression of the late genes are initiated. The molecular mechanisms responsible for this pronounced regulatory switch are as yet unclear (177; J. N. Miner and D. E. Hruby, Advances in Life Sciences: Molecular Genetics, in press). There are some VV genes whose expression does not follow these rules, being expressed at both early and late times during infection. These genes, such as the VV 7.5-kilodalton (kDa) gene, are termed constitutive, and although the same open reading frame is expressed, it is usually from alternative transcriptional start sites used prior to or after the onset of DNA replication (26). The VV late transcripts are novel in that they do not terminate at a distinct site and hence are heterogeneous in length and have a 3'-poly(A) tail and a 5'-poly(A) head which is added to the VV late transcripts by an unknown mechanism, although polymerase stuttering appears to be the most likely explanation (182 This process begins about 5 h postinfection with the appearance of membrane crescents which begin to form and envelop a portion of the viroplasm. The immature particle thus formed then migrates away from the virus factory and undergoes a complex series of morphogenetic condensation steps leading to the formation of a mature virion particle (30). During the maturation process the virus appears to package both viral and nonviral polypeptides (53) . This entire complicated process is well regulated and is remarkable in that only about 10 to 12 h is required to complete a single cycle of infection. VV produces 2,000 to 3,000 particles per infected cell, with a particle/infectious PFU ratio of approximately 1:10 to 1:20 (69) . Although VV does not transform cells, it is not lytic in the classical sense as infected cells do not lyse. Rather, the virus is able to move from the infected cell to the neighboring uninfected ones by cell fusion and syncytium formation, thereby causing a plaque, but most of the virus stays cell associated, thereby providing a convenient method for partial purification of virus, that is, collection of infected cells by centrifugation.
Advantages as a Vector Because of the unique cytoplasmic replication mode outlined above, VV not only provides an excellent experimental model system for molecular genetic investigations of the cis and trans factors required for replication and expression of genetic information, but also is uniquely suited to serve as a eucaryotic expression vector. The advantages of VV as a vector are outlined below.
Cytoplasmic replication. The cytoplasmic replication site (71) facilitates introduction of foreign genes into the viral genome by marker transfer and also the radiolabeling, detection, and isolation of proteins expressed by recombinant viruses. Furthermore, since the virus remains within the cytoplasmic compartment of infected cells and is apparently strictly lytic, potential complications of integration into the host cell genome or phenotypic transformation are not encountered. These are important considerations when a nuclear virus such as simian virus 40 is used as a vector (129) .
Broad host range. VV replicates in both primary cell cultures (e.g., chicken embryo fibroblasts) and many different cell culture lines (L929, CV-1, and HeLa) isolated from virtually any animal species (ranging from mosquitos to humans [52] ). VV will also grow in species of experimental animals (mice, rabbits, and guinea pigs) commonly used in the laboratory (72) . Thus, the virus can be used essentially as a eucaryotic shuttle vector with which to express a heterologous foreign protein of interest in a different cell type, primary cell culture, or even a whole animal.
Large viral genome. The 185-kilobase genome of VV readily tolerates both large insertions of foreign DNA (-25 kilobases) (145) and deletions of viral sequences (-20 kilobases) (116) . As opposed to smaller DNA viruses (107) , there seem to be no strict requirements or constraints on the absolute size of the VV DNA molecule required to be efficiently packaged or replicated. The ability to insert a large amount of foreign genetic information and its expression by the virus are important factors to consider when VV is used to construct a polyvalent vaccine containing antigens from several different pathogens (50, 125, 147) or perhaps antigens from several different serotypes of the same pathogen.
Viral transcriptional apparatus. VV transcribes its genome by using unique viral enzymes, viral transcription signals, and ancillary transcription factors (103, 104, 183) . From an operational standpoint, this means that, if one abuts a foreign gene directly to a VV promoter element, one can be reasonably sure that the foreign sequences will be actively transcribed during the course of the viral infection. Foreign transcripts will be capped and polyadenylated by VV enzymes and will serve as efficient messages for the translation of relatively high levels of the foreign protein within the infected cell. Evidence which has accumulated thus far indicates that the foreign proteins can be expected to be posttranslationally modified in an authentic manner, transported to the correct subcellular compartment, and in most cases to exhibit completely functional activity, be it enzymatic or structural. This is a distinct advantage over using bacterial, yeast, or nonmammalian virus (e.g., baculovirus) vectors to express mammalian proteins, as these systems often fail to modify the expressed proteins in the proper manner for full activity or antigenicity (107) .
Virus gene architecture. To date, no VV genes have been reported which contain intervening sequences; i.e., VV does not splice its primary transcripts. Thus, any contiguous coding sequence can be expressed from the context of the VV genome without concern about providing consensus splice signals in the correct locations. Likewise, since VV carries out its replication cycle in the cytoplasm, the requirement for incorporating the genetic information necessary to ensure the transport of foreign transcripts from the nucleus to the cytoplasm is obviated. These last considerations are of particular importance when attempting to express DNA sequences from bacteria or cDNA derived from cytoplasmic RNA viral templates, because these sequences have evolved for expression in non-nonuclear (i.e., cytoplasmic) environments. As such, not only do they lack in the correct location the necessary splice and transport signals for proper expression, but also they may fortuitously contain (160) (161) (162) .
Ultimately, whether VV vectors will be used in the human population may be decided by the question of risk versus benefit. In the event that the disease under consideration is non-life-threatening (e.g., common cold) or is controllable through the use of more traditional vaccines (e.g., poliovirus), then perhaps the use of VV-based vaccines may be contraindicated. This is especially true in view of potential cosmetic considerations such as the scarring associated with a primary poxvirus inoculation. On the other hand, if the diseases under discussion are serious and often fatal (such as malaria or hepatitis) or diseases for which there are no alternative therapeutic strategies, then the use of VV-based vaccines may well be worth the associated risk, especially in developing countries where routine access to medical treatment is limited (131, 171) .
MARKER TRANSFER METHODOLOGY Marker Transfer
The general method used to construct VV recombinants is diagrammed in Fig. 2 (112) . A recombination plasmid is constructed which consists of several elements. (i) One element is the foreign gene of interest abutted in the correct orientation to a VV promoter element. As noted above, the only constraint in this regard is that the insert must not contain any intervening sequences, i.e., be a genomic DNA lacking introns or a cDNA molecule. Aside from lacking introns, most other aspects (e.g., spatial relationships) of the chimeric VV-foreign gene construction appear to be relatively permissive. For optimal levels of expression, however, it is necessary to position the initiator ATG of the foreign gene's open reading frame in close proximity to the VV promoter, in a "good" ribosomal binding context (87) , with no alternative start codons available between the initiator ATG and the 5' end of the transcript. (ii) Another element is VV flanking DNA sequences which are necessary to catalyze homologous recombination and target the foreign gene insertion to a nonessential location in the viral genome. (iii) A third element is bacterial plasmid backbone containing an origin of replication and an antibiotic resistance locus to allow the plasmid to be grown and selected in Escherichia coli. Recombination plasmids, which have been purified by equilibrium centrifugation in cesium chloride gradients, are introduced into the cytoplasmic compartment of suitable host cells (usually either Ltk-or BSC-40 cells) by either a calcium phosphate-mediated transfection (63) or an electroporation procedure. The transfected cells are then superinfected with VV which initiates the viral replication cycle, including liberation and replication of the viral genome. If so desired, the order of infection and transfection can be reversed with little loss of marker transfer efficiency. In any case, although the precise mechanisms are not yet well understood, it is likely that, under the direction of virusencoded enzymes, the flanking VV DNA sequences of the recombination plasmid interact with homologous sequences present in the replicating viral DNA and catalyze insertion of the foreign sequences by a double-reciprocal crossover (homologous recombination). Evidence has been obtained to indicate that poxvirus DNA is subject to a relatively high rate of recombination during the normal course of infection (31), which undoubtedly facilitates this process. Provided that the insertion event has not inactivated an essential VV gene, such as DNA polymerase, the recombinant genome containing the foreign gene should be amplified by replication and packaged into infectious progeny recombinant virions.
Even in the absence of selection, recombinant VV production is remarkably efficient. In a typical marker transfer experiment, about 1 to 2% recombinants are produced in the progeny (although this number can be reduced several orders of magnitude depending on the size of the insert and the nature of the encoded protein). Recombinants can usually be found simply by using either a plaque hybridization (174) or an immunoblotting procedure. To facilitate this process, a number of methods to improve both the detection and the isolation of the desired recombinant have been developed, and these will be discussed in some detail later. Regardless of the detection scheme used, recombinant plaques of interest are picked and subjected to several rounds of plaque purification to ensure a pure population. The recombinant viruses are then ready for several levels of molecular analyses to ensure genomic authenticity and to determine whether the gene product of interest is being actively expressed.
Molecular Genetic Analyses of Recombinants DNA from recombinant virions is extracted and purified and digested with appropriate restriction endonucleases; the resulting DNA fragments are separated by agarose gel electrophoresis, and the gel is analyzed by Southern blotting procedures, using radioactive probes which are specific for either the region containing the insertion site or the foreign gene which was inserted (130) . These procedures are done to ensure, at least at this level of resolution, that an insert of the correct size and identity has been recombined into the anticipated location within the viral genome and that no other gross genomic alterations (rearrangements, secondsite insertions, or deletions) have occurred. Although illegitimate recombination occurs only rarely, because viral recombinants may be used as vaccines, genomic maps must be verified prior to use. To obtain more detailed information concerning the inserted DNA, recently developed polymerase chain reaction techniques (152) (130, 167) . Second, the 5' and 3' ends of the transcript are determined by a combination of nuclease S1 mapping and primer extension procedures to ensure that the chimeric RNA is initiated and terminated in the expected locations. These transcriptional analyses are important in the event that the foreign insert fortuitously contains cryptic VV transcriptional start or stop signals which will greatly attenuate the expression of the foreign gene product. If such problems do occur, they can be easily overcome by using site-directed mutagenesis (187) to introduce translationally silent mutations into the foreign insert, which will preserve the amino acid sequence of the derived gene product while destroying the cryptic VV transcriptional signals.
Assuming that the foreign DNA sequences are correctly transcribed, the final step in the characterization process is to determine whether the transcripts are actively translated within infected cells, whether the foreign proteins are stable, whether they are correctly transported and posttranslationally modified, and whether they are biologically active. In general, VV has been used in three ways as an expression vector: as a recombinant vaccine, to produce biopharmaceutical products, and as an expression vector for basic research. Obviously, the nature of the expressed protein dictates the types of protein assays that will be used to monitor the expression of the foreign gene product. For example, in the case of an antigen, antibody-directed reactions such as Western blotting of infected cell extracts or immunofluorescence of intact infected cells are used (130) . If the encoded protein is an enzyme, such as chloramphenicol acetyltransferase (120) (13) . Within a bacterial plasmid backbone, a single VV promoter is abutted to a polylinker region and flanked by genomic VV DNA targeting sequences. A number of different promoter elements have been used successfully in these constructions, including the F promoter (DNA sequences immediately upstream of the unique BamHI site of the VV HindIII F fragment) (119), the 11-kDa promoter from the HindIII A fragment (40), and the 7.5-kDa promoter found within the inverted terminal repeats present at both ends of the VV genomic DNA molecule (172) . These three promoters are each capable of directing efficient high-level expression of downstream foreign genes; however, they differ in the kinetics of expression. The F promoter is expressed as an immediate-early gene (prior to viral DNA replication), the 11-kDa promoter is expressed as a late gene (after viral DNA replication), and the 7.5-kDa promoter is expressed as a constitutive gene (throughout the replication cycle). It is likely that, as additional regions of the poxvirus genome are sequenced, new promoter elements will be described which will be equally useful for directing efficient or perhaps even regulated expression of inserted foreign genes. Along those lines, it is of interest to note that in recent studies the regulatory elements of the lac operon have successfully been transposed into the poxvirus genome to allow the inducible expression of inserted foreign genes (57) .
In any case, regardless of the promoter used, in the monoexpression vector system, foreign DNA sequences are inserted in a colinear orientation downstream of the VV promoter element to form a recombination vector. This type of plasmid has been used in concert with marker transfer techniques to construct the vast majority of VV recombinants that have been reported to date in the literature. Although effective, this approach is somewhat limiting when attempting to recombine large foreign inserts into the VV genome (which occurs at a low frequency) or when attempting to insert foreign DNA (such as a protease gene) whose expression is somewhat detrimental to viral replication. Under these conditions it is difficult, if not impossible, to find the recombinant virus of interest. To circumvent this problem, several dual coexpression insertion vector systems have been developed. In these cases, a VV promoterpolylinker expression cassette is abutted to a second VV promoter which drives either a selectable (e.g., neo [54, 55, 98] ) or an easily detectable (e.g., P-galactosidase [19, 75, 117] ) reporter gene, with the entire tandem array flanked by VV targeting DNA sequences (170) . Although the two cassettes are usually oriented in opposite directions (Fig. 3B) , there appears to be little transcriptional interference between neighboring VV genes so that alternative gene arrangements are equally active (55) . Using coexpression plasmids, the foreign gene is inserted into the plasmid, marker transfer is carried out, and recombinants are detected by expression of the reporter gene. In most, if not all, of the VV recombinants that express the reporter gene, the foreign gene is also convected into the viral genome and actively expressed.
All of the insertion vectors discussed thus far are constructed with bacterial plasmid vectors. It is also possible to design VV insertion vectors based on single-stranded M13 bacteriophage DNA (181) . These single-stranded insertion vectors have some experimental advantages, including ease of propagation and higher marker transfer frequency. Furthermore, the single-stranded DNA template is a suitable substrate for both DNA sequencing and site-directed mutagenic procedures, making this the system of choice when VV vectors are used to carry out structure-function investigations of foreign proteins.
Insertion Sites
It is believed that VV carries a large amount of genetic information which is apparently dispensable for growth in tissue culture. This notion is based on several lines of evidence, including (i) the isolation of spontaneous VV mutants that contain large (:20-kilobase) insertions or deletions of genomic DNA (116) ; (ii) the relatively small number of complementation groups to which the large number of temperature-sensitive mutants can be assigned (27); and (iii) random mutagenesis studies carried out on several regions of the VV genome which demonstrate that many VV genes can be inactivated with little apparent effect on viral replication (12, 124) . Taken together, these results suggest that a number of different nonessential loci within the VV genome are available for insertion sites for foreign DNA. Thus far, VV recombinants have been constructed by using a relatively limited number of insertion sites (Fig. 4) . These include the thymidine kinase (tk) gene (95) Using the coexpression recombination plasmids, selection can be achieved with reporter genes (such as luciferase [134] or 3-galactosidase [19] ) whose expression is easily detectable. In the latter case, the plaques arising from double recombinants expressing P-galactosidase can be easily identified among the background of wild-type plaques because they stain blue when the chromogenic substrate X-Gal (5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside) is included in the agar overlay. This detection scheme can also be used in the opposite manner by recombining foreign genes into a P-galactosidase gene present in the genome of the superinfecting virus. In this case, the recombinants of interest are those that do not stain blue, whereas the plaques arising from the input virus will appear blue.
The coexpression system can also be used together with a reporter gene to encode a biochemically selectable activity. The two systems that have proved most useful in this regard are neomycin phosphotransferase-G418 (55, 98) and guanosine phosphoribosyltransferase-mycophenolic acid (42). These selection schemes are particularly powerful in that only recombinant viruses grow and there is little or no possibility that the parental virus can spontaneously revert to drug resistance. With these selection schemes, if the initial marker transfer is carried out in the presence of drug, followed by one or two additional passages to rid the population of any wild-type virus replicating in the same cells as a recombinant virion, then virtually the entire progeny population will correspond to the desired recombinants. Individual plaques can then be picked and analyzed without any need for plaque hybridization techniques. The availability of such powerful selection schemes is especially important when maximum efficiency is needed, e.g., in attempting to produce large numbers of different recombinants or when inserting cDNA libraries into VV. In the future, as additional selection schemes are developed for other procaryotic and eucaryotic vectors, they will be adapted for use in concert with VV insertion plasmids.
APPLICATIONS OF VV VECTORS Prophylactic Vaccines
The most common use of and interest in VV as a vector is as a potential recombinant vaccine. The premise is to insert a gene encoding an antigen from a heterologous pathogen into VV and then use the recombinant virus as a live infectious vaccine with which to induce antigen-specific immune responses in recipient animals (51, 60, 78, 96) . In this way, immunity to the pathogenic agent is achieved without the risk of exposure to the pathogen. This approach has been used to construct candidate vaccines directed against viral (e.g., hepatitis) (111) , protozoal (e.g., malaria) (89) , bacterial (e.g., streptococcal pharyngitis and rheumatic fever) (46) , and even oncogenic (175) diseases of both humans and domestic animals. Most of the VV recombinants used to immunize animals are highly effective at inducing both humoral and cellular immunity. As (46) . Thus, the use of VV-M-protein recombinants has allowed the identification of a previously unrecognized cross-protective conserved M-protein epitope which should be effective in inducing antistreptococcal immunity. A similar approach, using VV vectors, should allow the identification of protective determinants present on other bacterial and viral pathogens for which no vaccine currently exists.
VOL. 3, 1990 on October 27, 2017 by guest http://cmr.asm.org/ FPV  FPV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV   VV   VV   CPV  VV   VV   VV  VV   VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV  VV   VV   VV  VV   38, 136, 137, 168  160  161  7  3, 21, 28, Possibly one of the most rewarding and promising areas in which VV vectors have been used is in the field of cell biology. VV recombinants have been used to express neuropeptides, growth factors, and receptor proteins (164) . The advantages of this approach are (i) appreciable (microgram) quantities of these proteins, which usually are found in only low concentrations, are expressed in a biologically active form; (ii) immunological reagents can be prepared with which to follow the synthesis and modification of the proteins within the cell; (iii) the expression of these proteins in heterologous cell types and in cells from different species is facilitated; and (iv) perhaps most important, directed genetics can be used to dissect structure-function relationships of cellular proteins rapidly.
Perhaps the most well-studied example of using VV vectors to investigate cellular processes is in the field of neurobiology, in which the technique was used as a novel approach to study neuropeptide maturation (73, (164) (165) (166) . Biologically active opioid peptide hormones are produced in a tissue-specific manner by differential proteolysis of larger protein precursors. Little is known about how these reactions are regulated, what enzymes are responsible for the cleavage reactions, or what features of the precursor molecules are essential for correct processing to occur. To address these questions, full-length cDNA inserts encoding human preproenkephalin (hPE) and mouse preproopiomelanocortin (mPOMC) precursors have been recombined into the VV genome. When used to infect nonsecretory cells such as BSC-40 monkey kidney lines, the VV:hPE and VV:mPOMC recombinants express uncleaved precursors, whereas infection of a secretory-competent cell line such as mouse AtT-20 cells results in the expression of fully processed peptides. This system now provides the ability to generate a series of site-specific VV:hPE and VV:mPOMC recombinants in which individual amino acid residues of the precursor molecules have been altered. The effects of these alterations on the posttranslational modification, proteolytic processing, and intracellular trafficking of neuropeptide precursors can then be assessed.
Recently, the gene encoding the yeast a-mating-factor protease (KEX2) was recombined in a fully functional form into VV. Surprisingly, it was possible to demonstrate that coinfection of BSC-40 cells with VV:POMC and VV:KEX2 results in the complete restoration of the authentic neuropeptide processing pathway. Having demonstrated that this reconstitution or trans-complementation approach will work with the yeast enzyme, it will now be of interest to extend this approach to identify the cognate cellular proteases that are usually uninvolved in catalyzing these reac- (Table 1) . These recombinants are being used to determine whether the viral proteins are immunogenic and, if so, whether the antibodies induced can neutralize the infectious virus. Likewise, by using these recombinant viruses to infect whole animals, the relative contributions and interactions of the humoral and cellular immune systems can be examined since VV is effective at priming both T-and B-cell-mediated responses. VV vectors together with this "dissection" approach to immunity are also being used to study a number of different virus-cell interactions, including those of type 1 herpes simplex virus (99) and lymphocytic choriomeningitis virus (97) .
Basic Research VV vectors can be used to express and manipulate any DNA sequences of interest, whether they encode antigens, enzymes, or structural proteins. Since the cloned sequences within the recombination vectors are suitable substrates for site-directed mutagenesis procedures, it is a relatively straightforward procedure to prepare a collection of VV recombinants expressing different genetically engineered forms of the same protein to address structure-function relationships. In this regard, it is of interest to note that there are two approaches to using VV vectors (Fig. 5) Whether or not we eventually use these vectors in their present form as vaccines in the clinical setting remains to be debated and experimentally tested. However, it is certain that the information generated by using these vectors in the laboratory will prove invaluable when formulating practical solutions to disease problems. Finally, it is likely that the potential of VV vectors is just beginning to be tapped. As additional information concerning the structure, function, and regulation of poxvirus genetic information becomes known, it is likely that new generations of VV vector systems will be developed. Therefore, rather than considering this contribution as a review, perhaps it would be more appropriate to view it as a progress report. 
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